FDA
-
-
-
-
-
-
-
POINT Biopharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
Lantheus Holdings (LNTH) and POINT Biopharma (PNT) Collaborate and Enter License Agreements for the Commercialization of PNT2002 & PNT2003
-
-
-
-
-
-
-
POINT Biopharma (PNT) Collaborates with Convergent Therapeutics to Evaluate CONV 01-α in Combination With PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer
-
-
-
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

